When we last looked at Lantheus in May, its stock was trading just under $80 a share. As a reminder, Lantheus Holdings, Inc.

Explore Lantheus Holdings stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for LNTH. Root And ZoomInfo Are Among Top 8 Mid-Cap Gainers Last Week (Feb 24-Feb ...

Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Lantheus (NASDAQ:LNTH – Get Free Report) had its price objective lowered by B. Riley from $127.00 to $122.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) reported 2024 financial and operational results on February 26 th, producing sales of over $1 billion for Pylarify during the calendar year. Other products ...

CytoSite will lead initial clinical development with Lantheus having an exclusive option ... of tumor cells by the immune system. CytoSite's products enable individually optimized treatments ...

In conclusion, Lantheus Holdings Inc.’s earnings call highlighted a strong revenue performance driven by key products and strategic acquisitions, despite facing challenges such as increased ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Lantheus Holdings (NASDAQ ... with potential for multiple commercially approved products in 2026. Definity maintained its market leadership position in ultrasound-enhancing agents during the ...

B. Riley lowered the firm’s price target on Lantheus (LNTH) to $122 from $127 and keeps a Buy rating on the shares. Competitor Telix’s (TLX) Gozellix received FDA approval for the next ...